CMJ Hospital, a beacon of healthcare for the poor & needy in Girgaon, Mumbai, with …
IlluminOss Subsidiary ABL Medical Developing Anti-Microbial Blue Light Fiber Technology!
ABL Medical Inc. a subsidiary of IlluminOss Medical Inc. In 2018, IlluminOss Medical began offering …
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it …
YASHODA HOSPITALS, Hyderabad SUCCESSFULLY TREATS ELDERLY MAN WITH CA. BUCCAL MUCOSA INFILTRATING INTO MANDIBLE
Yashoda Hospitals (Malakpet) Hyderabad, a leading healthcare institution, has successfully treated an elderly man aged …
Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), a pioneer in life …
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the …
Ocutrx Unveils OcuLenz AR/XR Headset, Aiding Vision for Patients with Advanced Macular Degeneration
Ocutrx Technologies, Inc., a leader in augmented reality (AR) and 3D technology for medical and …
Vesica Health Appoints Distinguished Urologic Oncologist Dr. William T. Lowrance to Chief Medical Officer
VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and …
First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from an …
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses …
